{"ticker": {"uuid": "99460c4f-9062-4932-b02d-63ff913cf073", "symbol": "XBRANE", "name": "Xbrane Biopharma AB (publ)", "exchange": "STO", "country": "SE", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Earnings call transcript: Xbrane Q2 2026 revenue rises as shipments resume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaVpyTkZFbW5hblVUYVU5VFBINFkzU3FVU09TQlM2MFBaaGpaWGVqOEhLRUlxVEg2M0NrVERILWJGX1lVaEl4blFvbnZmTlRYMktqdmtZZHcyUlg3YW1nVGxXVi1GckVDWWlYNXN1N3ZObUNsTzJUZnA1NFVKWnB5V2Y0TGlUOVF0aU9xYl9ueUFZTkFoelp2VkRmQi1VYURNSFBobGNZQ2F3Z0g1ZXNmS181dlUtZ3owWERVTllKLVZxVU1IcjBEaA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-17T08:33:40+00:00", "published_display": "17 Jul 2026 08:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBRANE: Q2 revenue reached SEK 46.8M, with resumed Ximluci sales and key cost reductions expected by 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxNckxNcVhhWklXckpsY015Z0h4RFIwY3JPMVFMMnRWQ2oxanc1dE1LcXdaWkRYQXZzbW02Nlo3X0NSSXdjLWtPVkxQcGhYMkFWNkdpVTdFeU1PSnRyYjB5QnU0VHc1MUNUcG5sOUlfTm9STVF0bTZrQ20wQ2YyZkZjNVFmXzQyVno2ZHdqR2s4YlJJN2JocWdZR3JiZDIzOU85cHhOUlhXZ2EwSG5lTTk4SE8yUFMtdUZET0ZTOFl5cm9pdFQ0V0RYeTdqbFYtMm54NTh5MVdYN3ZtRWxwSzVXZVc1eVVXLWFvWk12dWwtN0swc3V3dUQtbkRMUU4xeVFzQjJwOW5WbEluMFJSZXRKZzZyMk1obzJ0aGc?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T07:53:57+00:00", "published_display": "17 Jul 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBRANE: Ximluci\u24c7 drives growth as biosimilar pipeline advances, with strong cash position and cost focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOQ2FoLUpZN3R5c09kOTZBa1ZUVDRvV0hoUU1HQUQyZHgzS2JCNXYzU0RxVjlFX00xY2ZTZE1sWHI5bE14TjNLYWJ1QS1rTkFuQ1VmUk9fajFhZXE1eWZvMFAybklTWjZJSHluR3JDV0w1Ul9SWFc1Mks4Wm9FQk04QnpQWnhxaGNYWmRXVDdrQ01NVG9rUjlBazJoWkdHSmFPWWNTNHk3Z1hubHhDZEFBLU5BeUlEb2xwUmg5akppSGp4UXkyRFlqTTJOZ05QbGF3ZVRUckQ0aDJ2cm5IaTByQjVxWU1XcUc2cUFXOVE4bTdqVFFVQmI5RnVqZlNoVXVfNGRfRUJwdjF4ZTUxMkNQcmpR?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T07:46:18+00:00", "published_display": "17 Jul 2026 07:46", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane bolsters biosimilar pipeline as Ximluci drives revenue and FDA review advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPeTRRc0poajA4NkczRzU1dGpfQ1JjMUJ4SGNlU25SY3p5dEdHelVpaHBfa2Vhc05CU0N0WllOZUZNT0FTRE5pMnFLVDlGSkp3bW9TWTdhb1BaMktEZzVkVl9SNDAtN0tpX2RTc0tpYWJaMjVnMVk1YnJUVWJDZzVmVmczOG15ck9EczE5ZXItemJ0WjJYbUg0VUhPcTRFTTBGU1Q0aC1NWVZWTHRpSUNseEJaTGRtZVVTSlBPMDZwVnBwMUZwLTY0R3ZYR3RBcldqLVRJ?oc=5", "source_name": "TipRanks", "published_at": "2026-07-17T07:13:14+00:00", "published_display": "17 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane Biopharma's EBITDA loss widened in Q2", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNQVRBSDU2aWVmVDAzOGVBREhHTHlmNElGYkZ5SjU0dzVVSDVyLW02a3NpYVRBUVVlN1ctZm9PQ2hvZXliOENDYm9HVE1JSXlKX2VQaklld01RVFBhaTlraU4wbGZqNXpZbUEyTzZwN1I2VEI3R29aVHlxeUMwODRuZ254LUpqUmtJM011cVpRRWU1VHRCdnB6VjJwdzE2dw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-17T06:49:19+00:00", "published_display": "17 Jul 2026 06:49", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane Biopharma : releases Interim Report for January-June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRDlEQjVoZVBsR2dzSEp0UDFyNnRPMWFuZjI2NTIyQUtFd2RxY0NsS3U5UTFBTXZ5X3d0TjBtcFVWM3B4T2RjbEt1d18yVUgxTVkzbUtybFhpQXVwMEhOOUdnVEM4bkMxR2RXM0NKU09KakJqNlpqMHI2WUxEaEplNk5TV2YzdEppZmU5UFIxRzlpRWhHSVBjc0xMYXJfeXVXeUYtUjM2b1BJTVFGQVNueVJHVWhtUQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-17T06:33:05+00:00", "published_display": "17 Jul 2026 06:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane Biopharma releases Interim Report for January-June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOTU5XUmxWeXU2X3ZQQ3BQNXY1T0c3Smo3TE5hWTdxODNBWmVMb2FGeTFpeUVQa29QQWRrVlNTNktZNUdDb1BEb0JKaVAyQmVJSEdVUmpmSWI4M2FGVWtIVnhJQV9iajJ2OWs3UHZCdEFNLXNjQ0paUElhaHZtd0JlOXc5eTdtck9sZXYwTURGcC03ZnY3ZVRPakpPSEJJNTVJcERvYWVWc1A4WG01WjlYSzNxSkc3cExkd18ydXhrOWhaLVJ2S1F3?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T06:30:00+00:00", "published_display": "17 Jul 2026 06:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xbrane Biopharma AB \u2013 MUN:7XB0", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPSEFBT1daOHVKRVI3eXBQcVN3UlNhdGVPUUFSbTRudldYdmVEUVBBR3BybHFYOUM4UjUxU0JzSTBpOVFzaklHNG53YlNGS0xzNmRRV3pia3ZFX29XUTRWOUVmRWhHRGg1T2dvSkNCZ0h4NHRRaTZVOWRfWS1paUsxdE1hUjhJNzhvcUdkOTlLUkE1YlhFTEdvdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T06:54:43+00:00", "published_display": "06 Jul 2026 06:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Investors Shouldn't Be Surprised By Xbrane Biopharma AB (publ)'s (STO:XBRANE) 69% Share Price Plunge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQM3JJeWNzbzlRMFpKQ0FLaTRmVXNXYTNOUWQ2ZE5TUnJRM3Z0QU5SMlB1cnZzVW9NR1BlUnZBZ2tOWXhPSF9LVlQ5VG1jZXF0V0JjZndzcWVocEJIUzd6TFpzd203T2o1REQ5eXJZUVRiVElqX1pCY3JsZUwxdnJPd3VEbVRNTVVuNzFjV0Y1Tm5haklWWm1KOVhQcGdpcDlRQVczUENMZEF0Q2s5Q2dkZFFjNjJqQTkxRGxjYmotOE9TVWpjNDY4UkNvQ1U2RlE3VGlMUUFLNmRfOHNrbFBMcTFna3VXV21mTWd0ZdIB8gFBVV95cUxNcTFtSDU0QWlKdU9KRkMwQVhQTldEbmd3bzluU2J1cDhaM1VlaVlCc2wzb08ycmVaVk9UTDhmUFlvV3ZvY0dHN000ZHdtalpWc0pZSnVvalFwX2ctcnBzWERGM19qeWtiZ3NMWGJZOUFaX015bTB3R285aXpvSFNJOWJRLUctamo3RzdKTS1GcUVxNHdFSXFpZ0dNNVlHV3U3S2RJNzVzaFVTT2haRUtYODJGRG15Z3czSzNOMUtZN2FUZGxQZy1nUDNYekxJLVR3ODFwWTJWaFNiQmRGUWtYaUZhSmhOS0Q2RHNMV2N5ZDMyZw?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane on the FDA drama: \"We are taking it seriously\" but outlines the way forward", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNOWhFaXotSGY0TFAyV2xsalpZcnhiSXZ4emRfUTJSUXU1b0V4NWMtZ1hHdkpYVGwxQkZSX3pKU2xSVElhcVQxYjVsZ0FGUmg3cU1WMzBGQ1QxcDFuM2dGbWRENVhqeS0zdk91dXYzS2dpUHdzQks0bzJlU0xTNF9VQnBRU1ZVWFZGRnFrTHJfSEhrLUNWQmcxRGYxRU9GVWp3bXRRSlRkanRkWTJj?oc=5", "source_name": "Biostock", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech acquires Xbrane", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE80R0RrREluYnZLRVhHMzlOTkRJV1l4M210OXJKSTN6VGEzcWx6SnVmR3U4aEI0VGgxSlAyTDRWcFVucVZfX21DRW9OeUhIcEl3VDN1dnZpYkNSUGdfekRHa1VYSXFzenc0V0RDVkRLN3k?oc=5", "source_name": "Generics and Biosimilars Initiative", "published_at": "2025-05-03T08:48:13+00:00", "published_display": "03 May 2025 08:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane submits FDA application for Ximluci", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5MbGYxTWVHNHF3M2xrWmV5MC1tSEZybGVHbUhnQ2N3WExUb3VucTFKNEZfUXB4a1JIc0hqb2cwLUh0TlBZcWx0eTRhSlZabDJweFNvdTFVRlR3WGNFSmVaUEcybllTT1Q3MERBSVlDOU1fdEFQQU1NY3cxUFpEUQ?oc=5", "source_name": "Biostock", "published_at": "2025-01-02T08:00:00+00:00", "published_display": "02 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Earnings call transcript: Xbrane Q2 2026 revenue rises as shipments resume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOaVpyTkZFbW5hblVUYVU5VFBINFkzU3FVU09TQlM2MFBaaGpaWGVqOEhLRUlxVEg2M0NrVERILWJGX1lVaEl4blFvbnZmTlRYMktqdmtZZHcyUlg3YW1nVGxXVi1GckVDWWlYNXN1N3ZObUNsTzJUZnA1NFVKWnB5V2Y0TGlUOVF0aU9xYl9ueUFZTkFoelp2VkRmQi1VYURNSFBobGNZQ2F3Z0g1ZXNmS181dlUtZ3owWERVTllKLVZxVU1IcjBEaA?oc=5", "source_name": "Investing.com", "published_at": "2026-07-17T08:33:40+00:00", "published_display": "17 Jul 2026 08:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBRANE: Q2 revenue reached SEK 46.8M, with resumed Ximluci sales and key cost reductions expected by 2027", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgJBVV95cUxNckxNcVhhWklXckpsY015Z0h4RFIwY3JPMVFMMnRWQ2oxanc1dE1LcXdaWkRYQXZzbW02Nlo3X0NSSXdjLWtPVkxQcGhYMkFWNkdpVTdFeU1PSnRyYjB5QnU0VHc1MUNUcG5sOUlfTm9STVF0bTZrQ20wQ2YyZkZjNVFmXzQyVno2ZHdqR2s4YlJJN2JocWdZR3JiZDIzOU85cHhOUlhXZ2EwSG5lTTk4SE8yUFMtdUZET0ZTOFl5cm9pdFQ0V0RYeTdqbFYtMm54NTh5MVdYN3ZtRWxwSzVXZVc1eVVXLWFvWk12dWwtN0swc3V3dUQtbkRMUU4xeVFzQjJwOW5WbEluMFJSZXRKZzZyMk1obzJ0aGc?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T07:53:57+00:00", "published_display": "17 Jul 2026 07:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBRANE: Ximluci\u24c7 drives growth as biosimilar pipeline advances, with strong cash position and cost focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMikgJBVV95cUxOQ2FoLUpZN3R5c09kOTZBa1ZUVDRvV0hoUU1HQUQyZHgzS2JCNXYzU0RxVjlFX00xY2ZTZE1sWHI5bE14TjNLYWJ1QS1rTkFuQ1VmUk9fajFhZXE1eWZvMFAybklTWjZJSHluR3JDV0w1Ul9SWFc1Mks4Wm9FQk04QnpQWnhxaGNYWmRXVDdrQ01NVG9rUjlBazJoWkdHSmFPWWNTNHk3Z1hubHhDZEFBLU5BeUlEb2xwUmg5akppSGp4UXkyRFlqTTJOZ05QbGF3ZVRUckQ0aDJ2cm5IaTByQjVxWU1XcUc2cUFXOVE4bTdqVFFVQmI5RnVqZlNoVXVfNGRfRUJwdjF4ZTUxMkNQcmpR?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T07:46:18+00:00", "published_display": "17 Jul 2026 07:46", "sentiment": "positive", "sentiment_pct": 82, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane bolsters biosimilar pipeline as Ximluci drives revenue and FDA review advances", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPeTRRc0poajA4NkczRzU1dGpfQ1JjMUJ4SGNlU25SY3p5dEdHelVpaHBfa2Vhc05CU0N0WllOZUZNT0FTRE5pMnFLVDlGSkp3bW9TWTdhb1BaMktEZzVkVl9SNDAtN0tpX2RTc0tpYWJaMjVnMVk1YnJUVWJDZzVmVmczOG15ck9EczE5ZXItemJ0WjJYbUg0VUhPcTRFTTBGU1Q0aC1NWVZWTHRpSUNseEJaTGRtZVVTSlBPMDZwVnBwMUZwLTY0R3ZYR3RBcldqLVRJ?oc=5", "source_name": "TipRanks", "published_at": "2026-07-17T07:13:14+00:00", "published_display": "17 Jul 2026 07:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane Biopharma's EBITDA loss widened in Q2", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxNQVRBSDU2aWVmVDAzOGVBREhHTHlmNElGYkZ5SjU0dzVVSDVyLW02a3NpYVRBUVVlN1ctZm9PQ2hvZXliOENDYm9HVE1JSXlKX2VQaklld01RVFBhaTlraU4wbGZqNXpZbUEyTzZwN1I2VEI3R29aVHlxeUMwODRuZ254LUpqUmtJM011cVpRRWU1VHRCdnB6VjJwdzE2dw?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-17T06:49:19+00:00", "published_display": "17 Jul 2026 06:49", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane Biopharma : releases Interim Report for January-June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPRDlEQjVoZVBsR2dzSEp0UDFyNnRPMWFuZjI2NTIyQUtFd2RxY0NsS3U5UTFBTXZ5X3d0TjBtcFVWM3B4T2RjbEt1d18yVUgxTVkzbUtybFhpQXVwMEhOOUdnVEM4bkMxR2RXM0NKU09KakJqNlpqMHI2WUxEaEplNk5TV2YzdEppZmU5UFIxRzlpRWhHSVBjc0xMYXJfeXVXeUYtUjM2b1BJTVFGQVNueVJHVWhtUQ?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-17T06:33:05+00:00", "published_display": "17 Jul 2026 06:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane Biopharma releases Interim Report for January-June 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxOTU5XUmxWeXU2X3ZQQ3BQNXY1T0c3Smo3TE5hWTdxODNBWmVMb2FGeTFpeUVQa29QQWRrVlNTNktZNUdDb1BEb0JKaVAyQmVJSEdVUmpmSWI4M2FGVWtIVnhJQV9iajJ2OWs3UHZCdEFNLXNjQ0paUElhaHZtd0JlOXc5eTdtck9sZXYwTURGcC03ZnY3ZVRPakpPSEJJNTVJcERvYWVWc1A4WG01WjlYSzNxSkc3cExkd18ydXhrOWhaLVJ2S1F3?oc=5", "source_name": "TradingView", "published_at": "2026-07-17T06:30:00+00:00", "published_display": "17 Jul 2026 06:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xbrane Biopharma AB \u2013 MUN:7XB0", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPSEFBT1daOHVKRVI3eXBQcVN3UlNhdGVPUUFSbTRudldYdmVEUVBBR3BybHFYOUM4UjUxU0JzSTBpOVFzaklHNG53YlNGS0xzNmRRV3pia3ZFX29XUTRWOUVmRWhHRGg1T2dvSkNCZ0h4NHRRaTZVOWRfWS1paUsxdE1hUjhJNzhvcUdkOTlLUkE1YlhFTEdvdw?oc=5", "source_name": "TradingView", "published_at": "2026-07-06T06:54:43+00:00", "published_display": "06 Jul 2026 06:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Investors Shouldn't Be Surprised By Xbrane Biopharma AB (publ)'s (STO:XBRANE) 69% Share Price Plunge", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxQM3JJeWNzbzlRMFpKQ0FLaTRmVXNXYTNOUWQ2ZE5TUnJRM3Z0QU5SMlB1cnZzVW9NR1BlUnZBZ2tOWXhPSF9LVlQ5VG1jZXF0V0JjZndzcWVocEJIUzd6TFpzd203T2o1REQ5eXJZUVRiVElqX1pCY3JsZUwxdnJPd3VEbVRNTVVuNzFjV0Y1Tm5haklWWm1KOVhQcGdpcDlRQVczUENMZEF0Q2s5Q2dkZFFjNjJqQTkxRGxjYmotOE9TVWpjNDY4UkNvQ1U2RlE3VGlMUUFLNmRfOHNrbFBMcTFna3VXV21mTWd0ZdIB8gFBVV95cUxNcTFtSDU0QWlKdU9KRkMwQVhQTldEbmd3bzluU2J1cDhaM1VlaVlCc2wzb08ycmVaVk9UTDhmUFlvV3ZvY0dHN000ZHdtalpWc0pZSnVvalFwX2ctcnBzWERGM19qeWtiZ3NMWGJZOUFaX015bTB3R285aXpvSFNJOWJRLUctamo3RzdKTS1GcUVxNHdFSXFpZ0dNNVlHV3U3S2RJNzVzaFVTT2haRUtYODJGRG15Z3czSzNOMUtZN2FUZGxQZy1nUDNYekxJLVR3ODFwWTJWaFNiQmRGUWtYaUZhSmhOS0Q2RHNMV2N5ZDMyZw?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-11T08:00:00+00:00", "published_display": "11 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane on the FDA drama: \"We are taking it seriously\" but outlines the way forward", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNOWhFaXotSGY0TFAyV2xsalpZcnhiSXZ4emRfUTJSUXU1b0V4NWMtZ1hHdkpYVGwxQkZSX3pKU2xSVElhcVQxYjVsZ0FGUmg3cU1WMzBGQ1QxcDFuM2dGbWRENVhqeS0zdk91dXYzS2dpUHdzQks0bzJlU0xTNF9VQnBRU1ZVWFZGRnFrTHJfSEhrLUNWQmcxRGYxRU9GVWp3bXRRSlRkanRkWTJj?oc=5", "source_name": "Biostock", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alvotech acquires Xbrane", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE80R0RrREluYnZLRVhHMzlOTkRJV1l4M210OXJKSTN6VGEzcWx6SnVmR3U4aEI0VGgxSlAyTDRWcFVucVZfX21DRW9OeUhIcEl3VDN1dnZpYkNSUGdfekRHa1VYSXFzenc0V0RDVkRLN3k?oc=5", "source_name": "Generics and Biosimilars Initiative", "published_at": "2025-05-03T08:48:13+00:00", "published_display": "03 May 2025 08:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xbrane submits FDA application for Ximluci", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTE5MbGYxTWVHNHF3M2xrWmV5MC1tSEZybGVHbUhnQ2N3WExUb3VucTFKNEZfUXB4a1JIc0hqb2cwLUh0TlBZcWx0eTRhSlZabDJweFNvdTFVRlR3WGNFSmVaUEcybllTT1Q3MERBSVlDOU1fdEFQQU1NY3cxUFpEUQ?oc=5", "source_name": "Biostock", "published_at": "2025-01-02T08:00:00+00:00", "published_display": "02 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 64, "total_relevant": 12, "sentiment_summary": {"positive": 1, "negative": 1, "neutral": 10, "score": 52, "total": 12, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 4.4, "count": 8}, {"event": "earnings", "label": "Earnings", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 10.8, "latest_week": "2026-07-10", "one_week_move": 0.0, "four_week_move": 0.9, "twelve_week_move": -6.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.113248, "market_dynamics_buy_signal": false, "relative_strength": -41.033675, "fair_value_gap": -88.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 38.3784, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, +0.9% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 4}, {"label": "marketscreener.com", "count": 2}, {"label": "Biostock", "count": 2}, {"label": "Investing.com", "count": 1}, {"label": "TipRanks", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "Generics and Biosimilars Initiative", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 12}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 8}, {"label": "Earnings", "count": 3}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "12", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.0% over one week, +0.9% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Earnings call transcript: Xbrane Q2 2026 revenue rises as shipments resume"}], "updated_at": "2026-07-17T12:04:06.348693+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}